From transplant to novel cellular therapies in multiple myeloma: European Myeloma Network guidelines and future perspectives

Survival of myeloma patients has greatly improved with the use of autologous stem cell transplantation and novel agents, such as proteasome inhibitors, immunomodulatory drugs and monoclonal antibodies. Compared to bortezomib- and lenalidomide-based regimens alone, the addition of high-dose melphalan...

Descripción completa

Detalles Bibliográficos
Autores principales: Gay, Francesca, Engelhardt, Monika, Terpos, Evangelos, Wäsch, Ralph, Giaccone, Luisa, Auner, Holger W., Caers, Jo, Gramatzki, Martin, van de Donk, Niels, Oliva, Stefania, Zamagni, Elena, Garderet, Laurent, Straka, Christian, Hajek, Roman, Ludwig, Heinz, Einsele, Herman, Dimopoulos, Meletios, Boccadoro, Mario, Kröger, Nicolaus, Cavo, Michele, Goldschmidt, Hartmut, Bruno, Benedetto, Sonneveld, Pieter
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Ferrata Storti Foundation 2018
Materias:
Review Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5792264/
https://www.ncbi.nlm.nih.gov/pubmed/29217780
http://dx.doi.org/10.3324/haematol.2017.174573

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5792264/
https://www.ncbi.nlm.nih.gov/pubmed/29217780
http://dx.doi.org/10.3324/haematol.2017.174573

Ejemplares similares